Disease control rate (DCR) of 78% (7 of 9) in combination escalation arm of MDNA11 with Merck’s (known as MSD outside of Canada and the US) ...

Thomas Hutson, DO, PharmD, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib plus pembrolizumab in patients with advanced renal cell carcinoma.

Private investment in pharmaceutical research can't replace the NIH. Both public investment and the private sector are needed ...

TD Cowen downgraded Merck (MRK) to Hold from Buy with a price target of $100, down from $121. The firm says its Buy thesis “broke down” with ...

(RTTNews) - Merck (MRK) announced that Health Canada has granted approval for KEYTRUDA, Merck's anti-PD-1 therapy, as a treatment for adult patients with resectable Stage II, IIIA, or IIIB non ...

MSD’s checkpoint inhibitor Keytruda has been cleared by the FDA for use in newly diagnosed cervical cancer patients with less severe disease, becoming the first anti-PD-1/PD-L1 immunotherapy for ...

MSD’s Keytruda has become the first checkpoint inhibitor to show improved survival when used as adjuvant therapy after surgery to remove tumours in clear cell renal cell carcinoma (RCC ...

The firm initially upgraded the stock in early 2024, expecting a strong performance from Keytruda and Gardasil, a lack of major risks, and management’s efforts to extend Keytruda’s outlook.

MSD’s Keytruda initially gained approval in Canada in 2015. Credit: JHVEPhoto/Shutterstock. Health Canada has approved MSD’s anti-programmed cell death protein 1 (PD-1) therapy Keytruda for treating ...

plus KEYTRUDA ® (pembrolizumab), a PD-1 inhibitor, in patients with previously untreated locally advanced or metastatic urothelial cancer (la/mUC). The results showed a sustained overall survival (OS) ...

Welcome to the Free Icons repository! This repository provides a collection of over 23,000 high-quality icons that you can use freely in your design projects. Whether you're working on web development ...